tradingkey.logo

AbbVie Inc

ABBV

186.960USD

-14.790-7.33%
Close 04/04, 16:00ETQuotes delayed by 15 min
330.03BMarket Cap
77.87P/E TTM

AbbVie Inc

186.960

-14.790-7.33%
More Details of AbbVie Inc Company
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Company Info
Company codeABBV
Company nameAbbVie Inc
IPO dateJan 02, 2013
Founded at2012
CEOMr. Robert A. Michael, CPA
Number of employees55000
Security typeOrdinary Share
Fiscal year-endJan 02
Address1 N Waukegan Rd
CityNORTH CHICAGO
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code60064
Phone18479327900
Websitehttps://www.abbvie.com/
Company codeABBV
IPO dateJan 02, 2013
Founded at2012
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. Gonzalez
Mr. Richard A. Gonzalez
Executive Chairman of the Board
Executive Chairman of the Board
386.48K
-2.18%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
-17.22%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
133.43K
--
Mr. Glenn Fletcher Tilton
Mr. Glenn Fletcher Tilton
Independent Director
Independent Director
50.71K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
41.74K
--
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
37.26K
--
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
34.44K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
27.75K
--
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
15.29K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. Gonzalez
Mr. Richard A. Gonzalez
Executive Chairman of the Board
Executive Chairman of the Board
386.48K
-2.18%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
-17.22%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
133.43K
--
Mr. Glenn Fletcher Tilton
Mr. Glenn Fletcher Tilton
Independent Director
Independent Director
50.71K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
41.74K
--
Revenue Breakdown
Currency: USDUpdate time: 4 hours ago
Currency: USDUpdate time: 4 hours ago
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
11.72B
20.80%
Immunology-HUMIRA
8.99B
15.96%
Immunology-RINVOQ
5.97B
10.60%
Hematologic Oncology-IMBRUVICA
3.35B
5.94%
Neuroscience-Botox Therapeutic
3.28B
5.83%
Other
23.02B
40.87%
By RegionUSD
Name
Revenue
Proportion
United States
40.78B
72.39%
International
11.51B
20.42%
All other countries
3.03B
5.38%
Germany
1.47B
2.60%
Japan
1.12B
1.99%
Other
-1.57B
-2.79%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
11.72B
20.80%
Immunology-HUMIRA
8.99B
15.96%
Immunology-RINVOQ
5.97B
10.60%
Hematologic Oncology-IMBRUVICA
3.35B
5.94%
Neuroscience-Botox Therapeutic
3.28B
5.83%
Other
23.02B
40.87%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Global Advisors (US)
4.50%
Geode Capital Management, L.L.C.
2.10%
Capital Research Global Investors
1.92%
Other
76.65%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Global Advisors (US)
4.50%
Geode Capital Management, L.L.C.
2.10%
Capital Research Global Investors
1.92%
Other
76.65%
Type
Shareholder
Proportion
Investment Advisor
33.85%
Investment Advisor/Hedge Fund
29.79%
Research Firm
2.90%
Bank and Trust
2.23%
Pension Fund
2.22%
Sovereign Wealth Fund
1.52%
Insurance Company
0.63%
Hedge Fund
0.51%
Foundation
0.12%
Other
26.23%
Institutional Shareholding
Update time: Thu, Feb 20
Update time: Thu, Feb 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
5158
1.32B
74.38%
+12.54M
2024Q4
5219
1.31B
74.47%
+8.91M
2024Q3
4974
1.30B
73.54%
-7.44M
2024Q2
4916
1.30B
73.53%
+2.27M
2024Q1
4930
1.29B
72.58%
-1.47M
2023Q4
4882
1.28B
72.31%
-1.48M
2023Q3
4694
1.27B
71.87%
-12.06M
2023Q2
4688
1.26B
71.51%
-30.42M
2023Q1
4658
1.27B
71.97%
-18.58M
2022Q4
4628
1.27B
71.69%
-10.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
172.31M
9.74%
+1.45M
+0.85%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
90.08M
5.09%
+893.98K
+1.00%
Dec 31, 2024
State Street Global Advisors (US)
79.62M
4.5%
+553.55K
+0.70%
Dec 31, 2024
Geode Capital Management, L.L.C.
37.14M
2.1%
+983.89K
+2.72%
Dec 31, 2024
Capital Research Global Investors
33.98M
1.92%
+778.13K
+2.34%
Dec 31, 2024
JP Morgan Asset Management
33.90M
1.92%
+881.83K
+2.67%
Dec 31, 2024
Capital International Investors
28.53M
1.61%
-8.25M
-22.44%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
27.44M
1.55%
+3.60M
+15.10%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
25.10M
1.42%
+2.62M
+11.64%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.68M
1.28%
+844.34K
+3.87%
Dec 31, 2024
View more
Related ETFs
Update time: 16 hours ago
Update time: 16 hours ago
Name
Proportion
First Trust Morningstar Dividend Leaders Index Fund
9.82%
First Trust NASDAQ Pharmaceuticals ETF
8.98%
Proshares Ultra Health Care
6.94%
VanEck Pharmaceutical ETF
6.94%
Health Care Select Sector SPDR Fund
6.81%
iShares U.S. Healthcare ETF
6.71%
Goldman Sachs Future Health Care Equity ETF
6.07%
Fidelity MSCI Health Care Index ETF
5.92%
Invesco Pharmaceuticals ETF
5.84%
Themes US Cash Flow Champions ETF
5.7%
View more
First Trust Morningstar Dividend Leaders Index Fund
Proportion9.82%
First Trust NASDAQ Pharmaceuticals ETF
Proportion8.98%
Proshares Ultra Health Care
Proportion6.94%
VanEck Pharmaceutical ETF
Proportion6.94%
Health Care Select Sector SPDR Fund
Proportion6.81%
iShares U.S. Healthcare ETF
Proportion6.71%
Goldman Sachs Future Health Care Equity ETF
Proportion6.07%
Fidelity MSCI Health Care Index ETF
Proportion5.92%
Invesco Pharmaceuticals ETF
Proportion5.84%
Themes US Cash Flow Champions ETF
Proportion5.7%
Dividend
A total of 48.58B USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Sep 11, 2023
ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 22, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 16, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Oct 28, 2022
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 09, 2022
ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.